3B Blackbio DX Ltd
3B Blackbio DX Q3 FY24 earnings call: Revenue & Margins
Q3 FY24 investor presentation: what the company reported on revenue, margins and projects.
Based on 3B Blackbio DX Ltd's Q3 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q3 FY 2023-24 Diagnostics Business Revenue: ₹1,531.37 lakh (including ₹11.63 lakh COVID sales) vs ₹1,043.99 lakh in Q3 FY 2022-23; over 30% effective growth YoY (Page 15). Q3 FY 2023-24 EBITDA: ₹1,004.31 lakh vs ₹1,170.47 lakh in Q3 FY 2022-23 (YoY decrease) - Q3 FY 2023-24 Profit After Tax (PAT): ₹769.37 lakh vs ₹873.96 lakh in Q3 FY 2022-23 (YoY decrease) - Revenue fr
From 3B Blackbio DX Ltd's Q3 FY24 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3 FY 2023-24 Diagnostics Business Revenue: ₹1,531.37 lakh (including ₹11.63 lakh COVID sales) vs ₹1,043.99 lakh in Q3 FY 2022-23; over 30% effective growth YoY (Page 15).
- Export sales for molecular diagnostic kits in Q3 FY 2023-24: ₹267.20 lakh vs ₹219.89 lakh in Q3 FY 2022-23 (Page 15).
- Consolidated Q3 FY 2023-24 Total Revenue: ₹2,029.65 lakh vs ₹1,760.85 lakh in Q3 FY 2022-23 (Page 5).
- Consolidated Q3 FY 2023-24 Profit Before Tax: ₹1,115.20 lakh vs ₹989.68 lakh in Q3 FY 2022-23 (Page 5).
- Consolidated Q3 FY 2023-24 Profit After Tax: ₹851.69 lakh vs ₹771.40 lakh in Q3 FY 2022-23 (Page 5).
2 more points management made on revenue & sales performance
Profitability & Margins
See what 3B Blackbio DX Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company is continuously investing in building additional manufacturing and R&D facilities/capacities to support existing business verticals (Page 25).
- No specific capex amounts or timelines are detailed for these expansions.
- The amalgamation scheme with 3B BlackBio Biotech India Ltd is completed, creating a merged entity 3B BlackBio Dx Ltd, which is fully functional (Page 25).
- The UK subsidiary, TRUPCR® Europe Limited in Manchester, has moved to a larger, state-of-the-art facility with dedicated labs for Production, QC, R&D, and storage/dispatch (Page 20).
- TRUPCR® Europe is now ISO 13485:2016 accredited and has started manufacturing assays in the UK for EU customers ("Made in UK") (Page 20).
2 more points management made on capital expenditure plans
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what 3B Blackbio DX Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
3B Blackbio DX Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹50 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What 3B Blackbio DX Ltd's management said in earlier quarters
Frequently Asked Questions
What were 3B Blackbio DX Ltd Q3 FY24 results?
Q3 FY 2023-24 Diagnostics Business Revenue: ₹1,531.37 lakh (including ₹11.63 lakh COVID sales) vs ₹1,043.99 lakh in Q3 FY 2022-23; over 30% effective growth YoY (Page 15). Q3 FY 2023-24 EBITDA: ₹1,004.31 lakh vs ₹1,170.47 lakh in Q3 FY 2022-23 (YoY decrease) - Q3 FY 2023-24 Profit After Tax (PAT): ₹769.37 lakh vs ₹873.96 lakh in Q3 FY 2022-23 (YoY decrease) - Revenue fr
What is 3B Blackbio DX Ltd share price analysis?
3B Blackbio DX Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹1,132 Cr. Investors should review the full earnings analysis for detailed insights.
Is 3B Blackbio DX Ltd planning capital expenditure?
The company is continuously investing in building additional manufacturing and R&D facilities/capacities to support existing business verticals (Page 25).
Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.